|
1
|
Schaefer IM, DeMatteo RP and Serrano C:
The GIST of advances in treatment of advanced gastrointestinal
stromal tumor. Am Soc Clin Oncol Educ Book. 42:1–15.
2022.PubMed/NCBI
|
|
2
|
Raut CP, Espat NJ, Maki RG, Araujo DM,
Trent J, Williams TF, Purkayastha DD and DeMatteo RP: Efficacy and
tolerability of 5-year adjuvant imatinib treatment for patients
with resected intermediate- or high-risk primary gastrointestinal
stromal tumor: The PERSIST-5 clinical trial. JAMA Oncol.
4:e1840602018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leonardi GC, Falzone L, Salemi R, Zanghì
A, Spandidos DA, Mccubrey JA, Candido S and Libra M: Cutaneous
melanoma: From pathogenesis to therapy (Review). Int J Oncol.
52:1071–1080. 2018.PubMed/NCBI
|
|
4
|
Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J,
Dummer R, et al: Long-term outcomes with nivolumab plus ipilimumab
or nivolumab alone versus ipilimumab in patients with advanced
melanoma. J Clin Oncol. 40:127–137. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sukniam K, Manaise HK, Popp K, Popp R and
Gabriel E: Role of surgery in metastatic melanoma and review of
melanoma molecular characteristics. Cells. 13:4652024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Agaimy A, Wünsch PH, Sobin LH, Lasota J
and Miettinen M: Occurrence of other malignancies in patients with
gastrointestinal stromal tumors. Semin Diagn Pathol. 23:120–129.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vassos N, Agaimy A, Hohenberger W and
Croner RS: Coexistence of gastrointestinal stromal tumours (GIST)
and malignant neoplasms of different origin: Prognostic
implications. Int J Surg. 12:371–377. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nagai K, Matsumura Y, Nomura J, Inui M and
Tagawa T: A case of double cancer involving oral malignant melanoma
and gastrointestinal stromal tumor (GIST). Int J Oral Maxillofac
Surg. 34:328–330. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Linehan A, Harrold E, Pilson K and
McCaffrey J: Recurrent vulvar melanoma in a patient with
neurofibromatosis and gastrointestinal stromal tumour. BMJ Case
Rep. 12:e2247442019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Su YY, Chiang NJ, Wu CC and Chen LT:
Primary gastrointestinal stromal tumor of the liver in an anorectal
melanoma survivor: A case report. Oncol Lett. 10:2366–2370. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim YJ, Lee KA, Park TS, Baek HS and Jin
HY: Multiple metastasis of follicular variant of papillary thyroid
carcinoma coexistent with malignant melanoma. Korean J Intern Med.
33:634–637. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chau V and Bilusic M: Pembrolizumab in
combination with axitinib as first-line treatment for patients with
renal cell carcinoma (RCC): Evidence to date. Cancer Manag Res.
12:7321–7330. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng W, Sun G, Li Z, Wu F, Sun G, Cao H,
Zhou J and Ma Y: The effect of anlotinib combined with anti-PD-1 in
the treatment of gastric cancer. Front Surg. 9:8959822022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo J, Si L, Kong Y, Flaherty KT, Xu X,
Zhu Y, Corless CL, Li L, Li H, Sheng X, et al: Phase II,
open-label, single-arm trial of imatinib mesylate in patients with
metastatic melanoma harboring c-Kit mutation or amplification. J
Clin Oncol. 29:2904–2909. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carvajal RD, Antonescu CR, Wolchok JD,
Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ,
Chmielowski B, Lutzky J, et al: KIT as a therapeutic target in
metastatic melanoma. JAMA. 305:2327–2334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hodi FS, Corless CL, Giobbie-Hurder A,
Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R,
Weber JS, Gajewski TF, et al: Imatinib for melanomas harboring
mutationally activated or amplified KIT arising on mucosal, acral,
and chronically sun-damaged skin. J Clin Oncol. 31:3182–3190. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stahl M, Gedrich R, Peck R, LaVallee T and
Eder JP: Targeting KIT on innate immune cells to enhance the
antitumor activity of checkpoint inhibitors. Immunotherapy.
8:767–774. 2016. View Article : Google Scholar : PubMed/NCBI
|
